NINA BALANCHIVADZE

Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NORFOLK, VA NPI 1215225552

General Payments — all program years on this page

$12,782.14

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 29
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $6,980.43 across 12 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Consulting Fee $6,303.756
Long term medical supply or device loan $498.505
Food and Beverage $178.181

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Merck Sharp & Dohme Corporation $3,000.004
NOVARTIS PHARMACEUTICALS CORPORATION $2,870.437
Daiichi Sankyo Inc. $1,110.001

By program year

Program yearAmountRecords
2018 $52.544
2019 $63.024
2023 $5,686.159
2024 $6,980.4312

Records — PY2024 (12)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086774511 Novartis Pharmaceuticals Corporation $99.70 01/18/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086774515 Novartis Pharmaceuticals Corporation $99.70 02/16/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086774519 Novartis Pharmaceuticals Corporation $99.70 03/15/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086774523 Novartis Pharmaceuticals Corporation $99.70 04/18/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086774527 Novartis Pharmaceuticals Corporation $99.70 05/16/2024 Long term medical supply or device loan Undisputed 01/23/2026 View at CMS
1086774539 Novartis Pharmaceuticals Corporation $178.18 12/10/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1086774541 Novartis Pharmaceuticals Corporation $2,193.75 12/10/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1089396469 Daiichi Sankyo Inc. $1,110.00 05/29/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141805349 Merck Sharp & Dohme LLC $1,600.00 08/23/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141805351 Merck Sharp & Dohme LLC $400.00 04/19/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141805353 Merck Sharp & Dohme LLC $400.00 07/19/2024 Consulting Fee Undisputed 01/23/2026 View at CMS
1141805513 Merck Sharp & Dohme LLC $600.00 06/21/2024 Consulting Fee Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.